|
Uterine Natural Killer cells ([[natural killer cell|NK]]) secrete high levels of [[chemoattractant]]s, such as IFNγ. IFNγ dilates and thins the walls of maternal spiral arteries to enhance blood flow to the implantation site. This remodeling aids in the development of the placenta as it invades the uterus in its quest for nutrients. IFNγ knockout mice fail to initiate normal pregnancy-induced modification of [[decidual]] arteries. These models display abnormally low amounts of cells or [[necrosis]] of decidua.<ref name="pmid10899912">{{cite journal | author = Ashkar AA, Di Santo JP, Croy BA | title = Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy | journal = J. Exp. Med. | volume = 192 | issue = 2 | pages = 259–70 | date = July 2000 | pmid = 10899912 | pmc = 2193246 | doi = 10.1084/jem.192.2.259 }}</ref>
== TherapeuticUso useterapéutico ==
Interferon-γO IFNγ 1b isestá approvedutilizándose bypara thetratar U.S. Food and Drug Administration to treata [[chronicenfermidade granulomatousgranulomatosa diseasecrónica]].<ref name="pmid1372855">{{cite journal | author = Todd PA, Goa KL | title = Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease | journal = Drugs | volume = 43 | issue = 1 | pages = 111–22 | date = January 1992 | pmid = 1372855 | doi = 10.2165/00003495-199243010-00008 | url = | issn = }}</ref> and [[osteopetrosis]].<ref name="pmid1320672">{{cite journal | author = Key LL, Ries WL, Rodriguiz RM, Hatcher HC | title = Recombinant human interferon gamma therapy for osteopetrosis | journal = J. Pediatr. | volume = 121 | issue = 1 | pages = 119–24 | date = July 1992 | pmid = 1320672 | doi = 10.1016/S0022-3476(05)82557-0 | url = }}</ref>
ItNon wasestá notaprobado approvedo toseu treatuso idiopathicpara pulmonarytratar fibrosisa fibrose pulmonar (IPF)idiopática. InEn 2002, theen manufacturer[[EUA]] InterMuneas issuedafirmacións ado pressfabricante releaseInterMune sayingde thatque phaseos IIIensaios dataen demonstratedfase survival benefit in IPF and reducedIII mortalityreducían bynun 70% ina patients with mild to moderate disease. The U.S. Department of Justice charged that the release contained false and misleading statements. InterMune'smortalidade chiefdestes executivepacientes, Scottresultaron Harkonen, was accused of manipulating the trialser datafalsas, waspolo convictedque ino 2009xefe ofexecutivo wireda fraud,compañía andfoi wasacusado sentencedde tofalsificar finesos anddatos communitye service.condenado Harkonenpor appealed his conviction to the U.S. Court of Appeals for the Ninth Circuit,fraude andnos losttribunais.<ref name=Silverman_2013>{{cite journal | author = Silverman E | title = The line between scientific uncertainty and promotion of snake oil | journal = BMJ | volume = 347 | pages = f5687–f5687 | date = September 2013 | pmid = 24055923 | doi = 10.1136/bmj.f5687 }}</ref>
ItO isfármaco beingestá studiedsendo atprobado thepara [[Children’so Hospitalseu ofuso Philadelphia]]no fortratamento theda treatment of [[ataxia de Friedreich's ataxia]].<ref name=FA>{{cite web| publisher=FARA | accessdate=4 October 2013 | title=Open-label pilot study of interferon gamma-1b (Actimmune™) for the treatment of Friedreich Ataxia |date=10 June 2013 |url= http://www.curefa.org/_pdf/IFNgammaStudy082113.pdf|}}</ref>
AlthoughAínda notque officiallynon approved,está Interferon-γaprobado hasoficialmente alsoo beenseu shown touso, beo effectiveIFNγ intamén treatingdemostrou patientsser withefectivo moderateno totratamento severeda [[atopicdermatite dermatitisatópica]]. <ref>{{cite journal | author = Akhavan A, Rudikoff D | title = Atopic Dermatitis: Systemic Immunosuppressive Therapy | journal = Seminars in Cutaneous Medicine and Surgery | volume = 27 | issue = 2 | pages = 151-155 | date = 2008 | pmid = 18620137 | doi = 10.1016/j.sder.2008.04.004 | url = http://www.rheumatologynews.com/fileadmin/content_pdf/san/scms_pdf/vol27_i2_Systemic_Immunosuppressive_Therapy.pdf | accessdate = 16 October 2014 }}</ref> <ref>{{cite journal | author = Schneider LC, Baz Z, Zarcone C, Zurakowski D | title = Long-Term Therapy with Recombinant Interferon-Gamma (rIFN-γ) for Atopic Dermatitis | journal = Annals of Allergy, Asthma and Immunology | volume = 80 | issue = 3 | pages = 263-268 | date = 1998 | pmid = 9532976 | doi = 10.1016/S1081-1206(10)62968-7 | url = http://www.annallergy.org/article/S1081-1206(10)62968-7/abstract | accessdate = 16 October 2014 }}</ref>
<ref>{{cite journal | author = Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G | title = Recombinant interferon gamma therapy for atopic dermatitis. | journal = Journal of the American Academy of Dermatology | volume = 28 | issue = 2 Pt 1 | pages = 189-97 | year = 1993 | pmid = 8432915 }}</ref>
It is manufactured by InterMune as ''Actimmune'' and costs around USD300 per vial.{{citation needed|date=December 2011}}
==Interaccións==
| 